what is known already: SLC18A2 is a vesicular monoamine transporter that is essential in dopamine regulation. Dopamine can negatively regulate FSH and insulin secretion through the D2 receptor. study design, size, duration: This study was a cross-sectional examination in women with PCOS (n ¼ 319) and controls (n ¼ 220) from China.
Introduction
Polycystic ovary syndrome (PCOS) is a multifactorial disease caused by complex interactions between environmental factors and predisposing polygenic backgrounds (Vink et al., 2006) . Many genes have been associated with the etiology of the disease (Chen et al., 2011; Louwers et al., 2013; Mutharasan et al., 2013) . PCOS patients present with a variety of phenotypes, different metabolic traits and clinical manifestations (Apridonidze et al., 2005; Barber et al., 2006; Goodarzi et al., 2011; Kosova and Urbanek, 2013) , and these 'intermediate phenotypes' are also affected by genetic factors (Kevenaar et al., 2008) .
Follicle stimulating hormone (FSH) stimulates the growth and recruitment of immature ovarian follicles in the ovary, and abnormal levels of luteinizing hormone (LH) and FSH have been observed in PCOS (Balen et al., 1993; Jayasena and Franks, 2014) . In addition, insulin resistance plays a key role in the pathogenesis of PCOS (Dunaif et al., 1989; Franks, 1995; Toprak et al., 2001) . Solute carrier family 18-member A2 (SLC18A2) is a vesicular monoamine transporter that is essential to the activity of the monoaminergic systems. Importantly, dopamine negatively regulates FSH and insulin secretion through the D2 receptor (Nobels et al., 2000; Saisho et al., 2008; Simpson et al., 2012) . Thus, we hypothesized there might be a relationship between SCL18A2 and PCOS.
Until now, the roles of genetic variations of SLC18A2 in PCOS have been unexplored. In this study, we first determined the natural allelic variation at the SLC18A2 locus by resequencing the gene in 48 randomly selected Chinese PCOS patients. Tag SNPs were selected by pairwise linkage disequilibrium (LD) analysis. In addition, we compared the gene expression of SLC18A2 between PCOS patients and healthy controls in different tissues from NCBI's Gene Expression Omnibus (GEO) datasets. We next investigated whether the common genetic variants are associated with PCOS and explored the association of SLC18A2 genetic variations and haplotypes with several endocrine and metabolic traits. Finally, we characterized the functional activity of the variants by luciferase assay.
Materials and Methods

Study population
A total of 319 PCOS patients were recruited from the outpatient clinic of the Renji Hospital. The PCOS patients were diagnosed based on the criteria of the Androgen Excess Society, including clinical and/or biochemical signs of hyperandrogenemia plus oligoamenorrhea or polycystic ovaries (Azziz et al., 2006) . Patients with other causes of hyperandrogenism or menstrual disorders were excluded, i.e. 21-hydroxylase deficiency, Cushing's syndrome, androgen-secreting tumors and hypothyroidism (Welt et al., 2006) . None of the patients had taken hormonal medication, including oral contraceptives, for at least 3 months prior to starting the study. We recruited 220 healthy, non-diabetic female volunteers with regular menstrual cycles and without any genetic disorders to serve as the control group. Endocrine and biochemical parameters were measured to exclude hyperandrogenism, and ultrasound imaging was performed to exclude ovarian morphologies indicative of PCOS.
Standardized initial screening was performed on a random menstrual cycle day between 09:00 and 11:00 a.m. Fasting blood samples were taken on the third day of the follicular phase between 09:00 and 11:00 a.m. Estradiol, testosterone, sex-hormone-binding globulin, free androgen index, dehydroepiandrosterone sulfate, LH, FSH, fasting insulin and fasting plasma glucose were measured according to standard protocols. Both controls and patients also underwent a 75-g oral glucose tolerance test (OGTT), and blood was sampled for serum glucose and insulin concentrations before and at 0.5, 1, 2 and 3 h after the glucose load. The insulin sensitivity was evaluated by Matsuda index calculated as described (Matsuda and DeFronzo, 1999) . Glucose (AUCglu) and insulin (AUCins) areas under the curve at 3 h after the OGTT were calculated by the trapezoidal rule. The insulin secretion-sensitivity-2 index was measured as described previously (Retnakaran et al., 2009) .
All patients and controls were Han Chinese women recruited from the same area.
Ethical approval
The Fudan University Ethics Review Committee approved the study, and participants provided their written or verbal informed consent to participate in this study.
Systematic polymorphism discovery by resequencing
The strategy for Tag SNP selecting was performed as described previously . Forty-eight PCOS samples were randomly selected for resequencing. Genomic DNA was prepared from leukocytes in EDTA-anticoagulated blood using PureGene extraction columns (Qiagen, Dusseldorf, Germany), as described previously (Herrmann et al., 2000) . SLC18A2 genome sequences (NM_003054.4) were obtained from the UCSC Genome Bioinformatics website [http://genome.ucsc.edu (16 June 2016, date last accessed)] and used as a scaffold for primer design (Supplementary Table SI) . Target sequencing and polymorphism detection were performed as described previously .
Single nucleotide polymorphism (SNP) genotyping
The two common genetic variants, rs363282 and rs363238, were scored in 539 individuals (319 PCOS and 220 controls). The rs363282 and rs363238 variants were determined using the MassARRAY iPLEX Gold technology Association between SLC18A2 and FSH level in PCOS (Sequenom, San Diego, CA,USA) according to the methods published previously . We examined contamination and reliability of the platform by including four sample duplicates selected at random and four blank wells (H 2 O) in each 384-well plate. For the genotyping quality control, a call rate .90% for each 384-well plate, a concordance rate for the duplicates ≥99.7%, minor allele frequency (MAF) .3% and concordance rate .98% were considered acceptable.
Plasmid construction, mutagenesis and luciferase assay |The 2,284 bp 3 ′ -UTR of SLC18A2 (NM_003054.4) was amplified from a control sample genomic DNA with PCR primers incorporating XbaI restriction sites. The fragments were then cloned into luciferase reporter plasmid pGL3-promoter (Promega, Madison, WI, USA). In order to exclude the effect of other SNPs in the 2.2 kb of 3 ′ -UTR, creation of the rs363282 (A/G) and rs363238 (C/A) polymorphisms were achieved by site-directed mutagenesis (QuikChange; Stratagene, La Jolla, CA, USA) in two separate experiments with the plasmid pGL3-SLC18A2-3 ′ -UTR. Schematic of the constructed plasmid and corresponding mutant sites were demonstrated in Fig. 1A . Details of these primers are listed in Supplementary Table SI. Correct orientation (5 ′ -3 ′ ) and the sequences of the insert and mutation sites were verified by sequencing using three pairs of primers (SLC18A2-11, SLC18A2-12, SLC18A2-13). After plasmid growth under ampicillin selection in Escherichia coli and purification with QIAGEN Plasmid Midi Kits (QIAGEN), supercoiled plasmid DNA was transfected into 293T cells using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Transfection efficiency was determined by co-transfection with the pRL-CMV control plasmid that encodes the Renilla luciferase reporter gene (Promega, Madison, WI, USA). After transfection for 24 h, cells were lysed for sequential measurement with the dual luciferase assay system (Promega) in an ultra-sensitive GloMax 20/20 luminometer (Promega). Luciferase results are expressed as the ratio of firefly luciferase activity to Renilla luciferase activity from triplicate transfections.
Statistical analysis
Quantitative variables are expressed as the mean + standard error of the mean (SEM). The Hardy -Weinberg equilibrium test was performed using the x 2 -test run on PLINK [http://pngu.mgh.harvard.edu/purcell/plink/ (16 June 2016, date last accessed)]. Pairwise LD was tested using Haploview (Barrett et al., 2005) , and haplotype analysis was assessed using PLINK (Purcell et al., 2007) . One-way analysis of variance (ANOVA) or the Mann-Whitney U-test was used as appropriate to analyze the associations between genotype and clinical features. Clinical features of interest were chosen as dependent variables with age and BMI acting as the covariates. A P-value ,0.05 was considered statistically significant. Genotype and allele frequencies were compared using the x 2 -test. Analyses were performed using SPSS version 19 (SPSS, Inc., Chicago, IL, USA). In the power calculations, using the G*Power 3 [www.psycho.uni-duesseldorf.de/abteilungen/ aap/gpower3 (16 June 2016, date last accessed)] program, our sample size had .90% power to detect a significant (P , 0.05) association for alleles and genotypes when an effect size index of 0.5 was used. The gene expression analysis from NCBI's GEO datasets was conducted using the protocol, as described previously (Shi et al., 2012) .
Results
Clinical characteristics and the Tag SNP selection
The clinical characteristics of the PCOS patients and healthy controls are shown in Table I .
To identify genetic variants in SLC18A2, we resequenced the 16 exons and their adjacent regions. This included 1000 bp of the 5'-promoter and the 3 ′ -untranslated region (UTR) in the DNA from 48 PCOS patients (Supplementary Fig. S1 ). A total of 11 biallelic SNPs were identified, of which 2 were located in the coding region and 9 were located in the UTRs. Eight variants were common (MAF, minor allele frequency .10%), and all of these were in the 3 ′ -UTR. Among the 8 variants, rs111992368 was removed due to Hardy-Weinberg disequilibrium. MAF of 7 common SNPs was shown in Supplementary Table SII. Pairwise LD among seven common SNPs across the SLC18A2 locus was qualified as the r 2 parameter. The common variation was located within one LD block (Fig. 2 ). rs363282 and rs363238 were selected for further association study. Values are given as numbers or means + SE. P-Values are for comparison with control subjects and were obtained from either Student's t-test or Mann-Whitney U-test. Clinical indexes with significant differences (P , 0.05) are in bold. BMI, body mass index; E2, estradiol; T, testosterone; SHBG, sex-hormone-binding globulin; FAI, free androgen index; DHEAS, dehydroepiandrosteronesulfate; LH, serum luteinizing hormone; FSH, follicle stimulating hormone; FINS, fasting insulin; 0.5hINS, insulin at 0.5 h after the 75-g oral glucose tolerance test; FPG, fasting plasma glucose; 0.5hGLU, plasma glucose at 0.5 h after the 75-g oral glucose tolerance test. AUCins, the area under the insulin curve during the oral glucose test, AUCglu, the area under the glucose curve during the oral glucose tolerance test; ISSI-2, the insulin secretion-sensitivity-2 index.
Association and gene expression analysis of SLC18A2 between PCOS and controls Genotype and allele frequencies for the two polymorphisms in the PCOS cases did not differ from those in the healthy controls. The genotypes of the two polymorphisms were in Hardy-Weinberg equilibrium in both cases and controls (Table II) . The expression level of SLC18A2 varied in different tissues according to the analysis of the eight datasets from GEO (Supplementary Table SIII) . Although mRNA levels of SLC18A2 were up-regulated in muscles of insulin-resistant PCOS and skeletal muscles of obese women with PCOS, there were no significant difference in adipose tissue, theca cells, oocytes, granulosa cells, cultured cumulus cells or proliferative-phase endometrial cells (including endothelial cells, epithelial cells, mesenchymal cells and stromal cells).
The association between the SLC18A2 common variants rs363282 and rs363238 with serum FSH and insulin level in PCOS We adopted recessive modeling to perform the analysis; the samples were further divided into two subgroups based on different genetic variant genotypes: AA + AG genotype group and GG genotype group (rs363282), CC + AC genotype group and AA genotype group (rs363238). Both rs363282 and rs363238 were found to be significantly associated with serum FSH concentration (P ¼ 0.0004 and P ¼ 0.0001, respectively) and AUCins (P ¼ 0.04 and P ¼ 0.019) after adjusting for (color intensity decreases with decreasing r 2 value). There is no number noted, when r 2 is 1. Common SNPs: minor allele frequency .10%. Association between SLC18A2 and FSH level in PCOS age and BMI in the PCOS group (Table III) . After multiple testing correction, rs363282 and rs363238 remained significantly associated with FSH (P ¼ 0.005 and P ¼ 0.001, respectively), but showed no association with AUCins (P ¼ 0.52 and P ¼ 0.247, respectively). Patients with the rs363282-GG or rs363238-AA genotype showed increased levels of FSH (8.17 + 0.25 versus 7.14 + 0.16 and 8.33 + 0.26 versus 7.10 + 0.15, respectively) and AUCins (394.39 + 38.55 versus 338.87 + 10.80 and 407.89 + 42.22 versus 335.71 + 10.49, respectively). We pursued association analysis by analyzing the three genotypes separately (Supplementary Table SIV) . We still found there was a significant association between FSH level and all three kinds of genotypes. No association was found between the SNPs (rs363282 and rs363238) and metabolic traits in the 220 controls group (Supplementary Table SV) .
Furthermore, we analyzed association between the haplotype of the two variants with FSH and AUCins in PCOS patients. We found that the GA haplotype was significantly and positively correlated with the FSH level (P ¼ 0.011) and AUCins (P ¼ 0.011) (Table IV) , while significant negative correlations were found between the AC haplotype and the FSH level (P ¼ 0.018) and AUCins (P ¼ 0.041). The results were consistence with those of individual variants.
Functional effects of genetic variants in vitro
To investigate the functional effect of the genetic variants, we performed a luciferase assay in vitro. Sequence of the luciferase constructs and information of the polymorphism sites are listed in Supplementary Fig. S2 
Table II
Allele and genotype frequencies of rs363282 and rs363238 in women with polycystic ovary syndrome (n 5 319) and controls (n 5 220). Values are given as numbers or means + SE. Clinical indexes with significant differences (P , 0.05) are in bold. BMI, body mass index; E2, estradiol; T, testosterone; SHBG, sex-hormone-binding globulin; FAI, free androgen index; DHEAS, dehydroepiandrosterone sulfate; LH, serum luteinizing hormone; FSH, follicle stimulating hormone; AUCins, the area under the insulin curve during the oral glucose test, AUCglu, the area under the glucose curve during the oral glucose tolerance test; ISSI-2, the insulin secretion-sensitivity-2 index. minor G allele of rs363282 had a significantly lower luciferase activity than the major A allele (P ¼ 0.009, Fig. 1B) , and the minor A allele of rs363238 also had a significantly lower luciferase activity than the major C allele (P ¼ 0.009, Fig. 1C ).
Discussion
In this study, we investigated the role of common genetic variants at the SLC18A2 locus in the etiology and metabolic traits of PCOS. We found that no association between SLC18A2 variants and PCOS. Although higher SLC18A2 expression was found in muscles of PCOS patients from the GEO datasets, no significant difference was found in any other tissues. Therefore, SLC18A2 did not contribute to the risk of PCOS. However, two common genetic variants (rs363282 and rs363238) affect SLC18A2 expression through transcription or posttranscriptional mechanisms and are associated with FSH secretion in PCOS patients. SLC18A2 mediates the release of monoamines (Anlauf et al., 2006; Weihe and Eiden, 2000) , and the inhibitory effects of dopamine on gonadotrophin secretion has been extensively documented (Omeljaniuk et al., 1989; Sloley et al., 1992; Trudeau, 1997; Van Goor et al., 1998) . Chen et al. (2011) pursued the first genome-wide association study of PCOS and identified a few new loci, some of which were validated in subsequent studies (Shi et al., 2012; Louwers et al., 2013; Mutharasan et al., 2013) . However, only a few genes have been found to be associated with 'intermediate phenotypes' of PCOS (Kevenaar et al., 2008; Wang et al., 2010; Li et al., 2011; Zou et al., 2013) .
Chen et al. identified a locus in the cytochrome P450 family 19 subfamily A member 1 (CYP19A1) gene intron associated with FSH levels in a previous GWAS study that included 3495 Chinese men (Chen et al., 2013) . A recent GWAS study among European twins provided evidence that the genetic variants near the follicle stimulating hormone b polypeptide (FSHB) gene could influence both FSH and LH levels (Ruth et al., 2016) . The main reason for the different loci being associated with FSH levels in these two GWAS studies is the population distribution (Chinese men versus mainly European women). In our study, significant associations between genetic variants of SLC18A2 and FSH level were found in the PCOS group, but not in controls. Similar results were reported in other studies. For example, a diabetes risk variant in potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) was found to be associated with FSH levels in PCOS (Saxena and Welt, 2013) . Variants in an intron of FSHR in a case-control study (Saxena et al., 2015) and in the cancer susceptibility candidate 2 (CASC2) gene in a recent GWAS study (Hayes et al., 2015) were also observed to have the potential to regulate FSH levels in PCOS patients compared with controls. The most likely reason for this is that these alleles will increase the corresponding risk under disease background, and these findings provide the foundation for developing individualized treatments for specific subgroups of women with PCOS (Saxena et al., 2015) .
In our study, patients with the rs363282-GG and rs363238-AA genotype had higher FSH concentrations in PCOS group, while no association was found in the control group. Our luciferase experiments demonstrated that the rs363282-G and rs363238-A alleles lead to lower gene expression activity suggesting that these variants lead to decreased SLC18A2 activity. It has been shown that gonadotrophin secretion is negatively controlled by dopamine (Kanasaki et al., 2002) . Thus, decreased SLC18A2 activity might reduce dopamine release, which in turn would elevate FSH concentrations. The higher FSH levels in patients with the rs363282-GG and rs363238-AA alleles probably results in the accelerated follicle development described in previous studies (Maciel et al., 2004; Webber et al., 2003) , and this suggests that disrupting FSH stimulation of follicle development is important in the etiology of PCOS (Saxena et al., 2015; Hayes et al., 2015) . Thus, we provide evidence for both the association analysis and the functional study of the two SLC18A2 variants to support the conclusion that the two SNPs Association between SLC18A2 and FSH level in PCOS are functional and might play an important role in FSH secretion in PCOS. Because specific clinical parameters, including ovarian follicle and antiMüllerian hormone were not available in this study, roles of genetic variation of SLC18A2 in ovarian follicle and anti-Müllerian hormone cannot be evaluated. Therefore, other independent cohorts with more specific clinical parameters will be waiting for validating these results in subsequent investigations.
Many studies indicate that SLC18A2 plays an essential role in insulin regulation (Saisho et al., 2008; Sakano et al., 2014; Simpson et al., 2012) . In our study, although patients with the rs363282-GG and rs363238-AA genotypes and the GA haplotype have a higher AUCins index, the positive association was lost after multiple testing correction. Although our sample size is comparatively small, according to estimates with the G*Power 3 software when effect size d is 0.5, our sample power is 0.96, which means this sample size is sufficient for detecting most of the genetic factors responsible for the traits being investigated. Thus, we feel confident in our conclusion that there is no association between genetic variants in SLC18A2 and insulin secretion. Considering women with PCOS (25.72 + 0.35) were younger than control women (30.20 + 0.56) in the study samples, all the comparison between women with PCOS and control and association analysis across subgroups in PCOS have been adjusted for age during statistical analysis. Thus, the conclusion in this study should be convincing.
In conclusion, we have shown that SLC18A2 genetic variations are associated with FSH levels in PCOS patients, and we present a hypothetical mechanistic scheme in Fig. 3 . It is worthy to be further investigated in an independent cohort and future studies on the precise molecular mechanisms of how genetic variations in SLC18A2 affect FSH concentrations will yield new insights into the pathophysiology of PCOS.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
